Y

Ying K. Tam

Acuitas Therapeutics (Canada)

ORCID: 0000-0002-4083-5251

Publishes on RNA Interference and Gene Delivery, Immunotherapy and Immune Responses, SARS-CoV-2 and COVID-19 Research. 190 papers and 21.8k citations.

190Publications
21.8kTotal Citations
RNA Interference and Gene DeliveryImmunotherapy and Immune ResponsesSARS-CoV-2 and COVID-19 ResearchImmune Cell Function and InteractionAdvanced biosensing and bioanalysis techniques

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
Muthusamy Jayaraman, Steven M. Ansell, Barbara L. Mui et al.|Angewandte Chemie International Edition|2012
Cited by 1.2kOpen Access

Special (lipid) delivery: The role of the ionizable lipid pK(a) in the in vivo delivery of siRNA by lipid nanoparticles has been studied with a large number of head group modifications to the lipids. A tight correlation between the lipid pK(a) value and silencing of the mouse FVII gene (FVII ED(50) ) was found, with an optimal pK(a) range of 6.2-6.5. The most potent cationic lipid from this study has ED(50) levels around 0.005 mg kg(-1) in mice and less than 0.03 mg kg(-1) in non-human primates.